

Global IL-17 Inhibitors for Psoriasis Market Growth 2026-2032

<https://marketpublishers.com/r/G39B79B76209EN.html>

Date: January 2026

Pages: 104

Price: US\$ 3,660.00 (Single User License)

ID: G39B79B76209EN

Abstracts

The global IL-17 Inhibitors for Psoriasis market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

IL-17 inhibitors for psoriasis are a class of biologic drugs designed to target and block the activity of interleukin-17 (IL-17), a pro-inflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. By inhibiting IL-17, these drugs reduce the excessive immune response and help control the symptoms of moderate to severe plaque psoriasis. Examples of IL-17 inhibitors include secukinumab, ixekizumab, brodalumab and so on.

United States market for IL-17 Inhibitors for Psoriasis is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for IL-17 Inhibitors for Psoriasis is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for IL-17 Inhibitors for Psoriasis is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key IL-17 Inhibitors for Psoriasis players cover UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the ?IL-17 Inhibitors for Psoriasis Industry Forecast? looks at past sales and reviews total world IL-17 Inhibitors for

Psoriasis sales in 2025, providing a comprehensive analysis by region and market sector of projected IL-17 Inhibitors for Psoriasis sales for 2026 through 2032. With IL-17 Inhibitors for Psoriasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world IL-17 Inhibitors for Psoriasis industry.

This Insight Report provides a comprehensive analysis of the global IL-17 Inhibitors for Psoriasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on IL-17 Inhibitors for Psoriasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global IL-17 Inhibitors for Psoriasis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for IL-17 Inhibitors for Psoriasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global IL-17 Inhibitors for Psoriasis.

This report presents a comprehensive overview, market shares, and growth opportunities of IL-17 Inhibitors for Psoriasis market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Bimelizumab

Secukinumab

Ixekizumab

Brodalumab

Vunakizumab

Xeligekimab

Other

Segmentation by Application:

Hospital and Clinic

Pharmacy

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

UCB

Eli Lilly

Novartis

Ortho Dermatologics

LEO Pharma

Kyowa Kirin

Jiangsu Hengrui Pharmaceuticals

Chongqing Genrix Biopharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global IL-17 Inhibitors for Psoriasis market?

What factors are driving IL-17 Inhibitors for Psoriasis market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do IL-17 Inhibitors for Psoriasis market opportunities vary by end market size?

How does IL-17 Inhibitors for Psoriasis break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global IL-17 Inhibitors for Psoriasis Annual Sales 2021-2032

- 2.1.2 World Current & Future Analysis for IL-17 Inhibitors for Psoriasis by Geographic Region, 2021, 2025 & 2032

- 2.1.3 World Current & Future Analysis for IL-17 Inhibitors for Psoriasis by Country/Region, 2021, 2025 & 2032

2.2 IL-17 Inhibitors for Psoriasis Segment by Type

- 2.2.1 Bimelizumab

- 2.2.2 Secukinumab

- 2.2.3 Ixekizumab

- 2.2.4 Brodalumab

- 2.2.5 Vunakizumab

- 2.2.6 Xeligekimab

- 2.2.7 Other

- 2.2.8 IL-17 Inhibitors for Psoriasis Sales by Type

- 2.2.8.1 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)

- 2.2.8.2 Global IL-17 Inhibitors for Psoriasis Revenue and Market Share by Type (2021-2026)

- 2.2.8.3 Global IL-17 Inhibitors for Psoriasis Sale Price by Type (2021-2026)

2.3 IL-17 Inhibitors for Psoriasis Segment by Application

- 2.3.1 Hospital and Clinic

- 2.3.2 Pharmacy

- 2.3.3 Other

- 2.3.4 IL-17 Inhibitors for Psoriasis Sales by Application

2.3.4.1 Global IL-17 Inhibitors for Psoriasis Sale Market Share by Application (2021-2026)

2.3.4.2 Global IL-17 Inhibitors for Psoriasis Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global IL-17 Inhibitors for Psoriasis Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global IL-17 Inhibitors for Psoriasis Breakdown Data by Company

3.1.1 Global IL-17 Inhibitors for Psoriasis Annual Sales by Company (2021-2026)

3.1.2 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Company (2021-2026)

3.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue by Company (2021-2026)

3.2.1 Global IL-17 Inhibitors for Psoriasis Revenue by Company (2021-2026)

3.2.2 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company (2021-2026)

3.3 Global IL-17 Inhibitors for Psoriasis Sale Price by Company

3.4 Key Manufacturers IL-17 Inhibitors for Psoriasis Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers IL-17 Inhibitors for Psoriasis Product Location Distribution

3.4.2 Players IL-17 Inhibitors for Psoriasis Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR IL-17 INHIBITORS FOR PSORIASIS BY GEOGRAPHIC REGION

4.1 World Historic IL-17 Inhibitors for Psoriasis Market Size by Geographic Region (2021-2026)

4.1.1 Global IL-17 Inhibitors for Psoriasis Annual Sales by Geographic Region (2021-2026)

4.1.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic IL-17 Inhibitors for Psoriasis Market Size by Country/Region (2021-2026)

4.2.1 Global IL-17 Inhibitors for Psoriasis Annual Sales by Country/Region

(2021-2026)

4.2.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue by Country/Region

(2021-2026)

4.3 Americas IL-17 Inhibitors for Psoriasis Sales Growth

4.4 APAC IL-17 Inhibitors for Psoriasis Sales Growth

4.5 Europe IL-17 Inhibitors for Psoriasis Sales Growth

4.6 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Growth

5 AMERICAS

5.1 Americas IL-17 Inhibitors for Psoriasis Sales by Country

5.1.1 Americas IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)

5.1.2 Americas IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026)

5.2 Americas IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)

5.3 Americas IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC IL-17 Inhibitors for Psoriasis Sales by Region

6.1.1 APAC IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026)

6.1.2 APAC IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026)

6.2 APAC IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)

6.3 APAC IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe IL-17 Inhibitors for Psoriasis by Country

7.1.1 Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)

- 7.1.2 Europe IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026)
- 7.2 Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
- 7.3 Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa IL-17 Inhibitors for Psoriasis by Country
 - 8.1.1 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026)
- 8.2 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
- 8.3 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of IL-17 Inhibitors for Psoriasis
- 10.3 Manufacturing Process Analysis of IL-17 Inhibitors for Psoriasis
- 10.4 Industry Chain Structure of IL-17 Inhibitors for Psoriasis

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel

- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 IL-17 Inhibitors for Psoriasis Distributors
- 11.3 IL-17 Inhibitors for Psoriasis Customer

12 WORLD FORECAST REVIEW FOR IL-17 INHIBITORS FOR PSORIASIS BY GEOGRAPHIC REGION

- 12.1 Global IL-17 Inhibitors for Psoriasis Market Size Forecast by Region
 - 12.1.1 Global IL-17 Inhibitors for Psoriasis Forecast by Region (2027-2032)
 - 12.1.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global IL-17 Inhibitors for Psoriasis Forecast by Type (2027-2032)
- 12.7 Global IL-17 Inhibitors for Psoriasis Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

- 13.1 UCB
 - 13.1.1 UCB Company Information
 - 13.1.2 UCB IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
 - 13.1.3 UCB IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.1.4 UCB Main Business Overview
 - 13.1.5 UCB Latest Developments
- 13.2 Eli Lilly
 - 13.2.1 Eli Lilly Company Information
 - 13.2.2 Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
 - 13.2.3 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.2.4 Eli Lilly Main Business Overview
 - 13.2.5 Eli Lilly Latest Developments
- 13.3 Novartis
 - 13.3.1 Novartis Company Information
 - 13.3.2 Novartis IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
 - 13.3.3 Novartis IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin

(2021-2026)

13.3.4 Novartis Main Business Overview

13.3.5 Novartis Latest Developments

13.4 Ortho Dermatologics

13.4.1 Ortho Dermatologics Company Information

13.4.2 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

13.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Ortho Dermatologics Main Business Overview

13.4.5 Ortho Dermatologics Latest Developments

13.5 LEO Pharma

13.5.1 LEO Pharma Company Information

13.5.2 LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

13.5.3 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 LEO Pharma Main Business Overview

13.5.5 LEO Pharma Latest Developments

13.6 Kyowa Kirin

13.6.1 Kyowa Kirin Company Information

13.6.2 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

13.6.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Kyowa Kirin Main Business Overview

13.6.5 Kyowa Kirin Latest Developments

13.7 Jiangsu Hengrui Pharmaceuticals

13.7.1 Jiangsu Hengrui Pharmaceuticals Company Information

13.7.2 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

13.7.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview

13.7.5 Jiangsu Hengrui Pharmaceuticals Latest Developments

13.8 Chongqing Genrix Biopharmaceutical

13.8.1 Chongqing Genrix Biopharmaceutical Company Information

13.8.2 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

13.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Chongqing Genrix Biopharmaceutical Main Business Overview

13.8.5 Chongqing Genrix Biopharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. IL-17 Inhibitors for Psoriasis Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. IL-17 Inhibitors for Psoriasis Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Bimeelizumab

Table 4. Major Players of Secukinumab

Table 5. Major Players of Ixekizumab

Table 6. Major Players of Brodalumab

Table 7. Major Players of Vunakizumab

Table 8. Major Players of Xeligezimab

Table 9. Major Players of Other

Table 10. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)

Table 11. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)

Table 12. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & (\$ million)

Table 13. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026)

Table 14. Global IL-17 Inhibitors for Psoriasis Sale Price by Type (2021-2026) & (US\$/Unit)

Table 15. Global IL-17 Inhibitors for Psoriasis Sale by Application (2021-2026) & (K Units)

Table 16. Global IL-17 Inhibitors for Psoriasis Sale Market Share by Application (2021-2026)

Table 17. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & (\$ million)

Table 18. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2021-2026)

Table 19. Global IL-17 Inhibitors for Psoriasis Sale Price by Application (2021-2026) & (US\$/Unit)

Table 20. Global IL-17 Inhibitors for Psoriasis Sales by Company (2021-2026) & (K Units)

Table 21. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Company (2021-2026)

Table 22. Global IL-17 Inhibitors for Psoriasis Revenue by Company (2021-2026) & (\$ millions)

Table 23. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company (2021-2026)

Table 24. Global IL-17 Inhibitors for Psoriasis Sale Price by Company (2021-2026) & (US\$/Unit)

Table 25. Key Manufacturers IL-17 Inhibitors for Psoriasis Producing Area Distribution and Sales Area

Table 26. Players IL-17 Inhibitors for Psoriasis Products Offered

Table 27. IL-17 Inhibitors for Psoriasis Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 28. New Products and Potential Entrants

Table 29. Market M&A Activity & Strategy

Table 30. Global IL-17 Inhibitors for Psoriasis Sales by Geographic Region (2021-2026) & (K Units)

Table 31. Global IL-17 Inhibitors for Psoriasis Sales Market Share Geographic Region (2021-2026)

Table 32. Global IL-17 Inhibitors for Psoriasis Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 33. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Geographic Region (2021-2026)

Table 34. Global IL-17 Inhibitors for Psoriasis Sales by Country/Region (2021-2026) & (K Units)

Table 35. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Country/Region (2021-2026)

Table 36. Global IL-17 Inhibitors for Psoriasis Revenue by Country/Region (2021-2026) & (\$ millions)

Table 37. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Country/Region (2021-2026)

Table 38. Americas IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)

Table 39. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026)

Table 40. Americas IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026) & (\$ millions)

Table 41. Americas IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)

Table 42. Americas IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)

Table 43. APAC IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026) & (K Units)

Table 44. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2021-2026)

- Table 45. APAC IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026) & (\$ millions)
- Table 46. APAC IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
- Table 47. APAC IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
- Table 48. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
- Table 49. Europe IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026) & (\$ millions)
- Table 50. Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
- Table 51. Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
- Table 52. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
- Table 53. Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2021-2026)
- Table 54. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
- Table 55. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
- Table 56. Key Market Drivers & Growth Opportunities of IL-17 Inhibitors for Psoriasis
- Table 57. Key Market Challenges & Risks of IL-17 Inhibitors for Psoriasis
- Table 58. Key Industry Trends of IL-17 Inhibitors for Psoriasis
- Table 59. IL-17 Inhibitors for Psoriasis Raw Material
- Table 60. Key Suppliers of Raw Materials
- Table 61. IL-17 Inhibitors for Psoriasis Distributors List
- Table 62. IL-17 Inhibitors for Psoriasis Customer List
- Table 63. Global IL-17 Inhibitors for Psoriasis Sales Forecast by Region (2027-2032) & (K Units)
- Table 64. Global IL-17 Inhibitors for Psoriasis Revenue Forecast by Region (2027-2032) & (\$ millions)
- Table 65. Americas IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
- Table 66. Americas IL-17 Inhibitors for Psoriasis Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 67. APAC IL-17 Inhibitors for Psoriasis Sales Forecast by Region (2027-2032) & (K Units)
- Table 68. APAC IL-17 Inhibitors for Psoriasis Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 69. Europe IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)

Table 70. Europe IL-17 Inhibitors for Psoriasis Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 71. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)

Table 72. Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 73. Global IL-17 Inhibitors for Psoriasis Sales Forecast by Type (2027-2032) & (K Units)

Table 74. Global IL-17 Inhibitors for Psoriasis Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 75. Global IL-17 Inhibitors for Psoriasis Sales Forecast by Application (2027-2032) & (K Units)

Table 76. Global IL-17 Inhibitors for Psoriasis Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 77. UCB Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 78. UCB IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

Table 79. UCB IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 80. UCB Main Business

Table 81. UCB Latest Developments

Table 82. Eli Lilly Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 83. Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

Table 84. Eli Lilly IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 85. Eli Lilly Main Business

Table 86. Eli Lilly Latest Developments

Table 87. Novartis Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 88. Novartis IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

Table 89. Novartis IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 90. Novartis Main Business

Table 91. Novartis Latest Developments

Table 92. Ortho Dermatologics Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 93. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

Table 94. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 95. Ortho Dermatologics Main Business

Table 96. Ortho Dermatologics Latest Developments

Table 97. LEO Pharma Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 98. LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

Table 99. LEO Pharma IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 100. LEO Pharma Main Business

Table 101. LEO Pharma Latest Developments

Table 102. Kyowa Kirin Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 103. Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

Table 104. Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 105. Kyowa Kirin Main Business

Table 106. Kyowa Kirin Latest Developments

Table 107. Jiangsu Hengrui Pharmaceuticals Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 108. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

Table 109. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 110. Jiangsu Hengrui Pharmaceuticals Main Business

Table 111. Jiangsu Hengrui Pharmaceuticals Latest Developments

Table 112. Chongqing Genix Biopharmaceutical Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 113. Chongqing Genix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications

Table 114. Chongqing Genix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 115. Chongqing Genix Biopharmaceutical Main Business

Table 116. Chongqing Genix Biopharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of IL-17 Inhibitors for Psoriasis
- Figure 2. IL-17 Inhibitors for Psoriasis Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global IL-17 Inhibitors for Psoriasis Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global IL-17 Inhibitors for Psoriasis Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. IL-17 Inhibitors for Psoriasis Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. IL-17 Inhibitors for Psoriasis Sales Market Share by Country/Region (2025)
- Figure 10. IL-17 Inhibitors for Psoriasis Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Bimelizumab
- Figure 12. Product Picture of Secukinumab
- Figure 13. Product Picture of Ixekizumab
- Figure 14. Product Picture of Brodalumab
- Figure 15. Product Picture of Vunakizumab
- Figure 16. Product Picture of Xeligekimab
- Figure 17. Product Picture of Other
- Figure 18. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type in 2026
- Figure 19. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026)
- Figure 20. IL-17 Inhibitors for Psoriasis Consumed in Hospital and Clinic
- Figure 21. Global IL-17 Inhibitors for Psoriasis Market: Hospital and Clinic (2021-2026) & (K Units)
- Figure 22. IL-17 Inhibitors for Psoriasis Consumed in Pharmacy
- Figure 23. Global IL-17 Inhibitors for Psoriasis Market: Pharmacy (2021-2026) & (K Units)
- Figure 24. IL-17 Inhibitors for Psoriasis Consumed in Other
- Figure 25. Global IL-17 Inhibitors for Psoriasis Market: Other (2021-2026) & (K Units)
- Figure 26. Global IL-17 Inhibitors for Psoriasis Sale Market Share by Application (2025)
- Figure 27. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application in 2026
- Figure 28. IL-17 Inhibitors for Psoriasis Sales by Company in 2026 (K Units)

Figure 29. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Company in 2026

Figure 30. IL-17 Inhibitors for Psoriasis Revenue by Company in 2026 (\$ millions)

Figure 31. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company in 2026

Figure 32. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Geographic Region (2021-2026)

Figure 33. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Geographic Region in 2026

Figure 34. Americas IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)

Figure 35. Americas IL-17 Inhibitors for Psoriasis Revenue 2021-2026 (\$ millions)

Figure 36. APAC IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)

Figure 37. APAC IL-17 Inhibitors for Psoriasis Revenue 2021-2026 (\$ millions)

Figure 38. Europe IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)

Figure 39. Europe IL-17 Inhibitors for Psoriasis Revenue 2021-2026 (\$ millions)

Figure 40. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)

Figure 41. Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue 2021-2026 (\$ millions)

Figure 42. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Country in 2026

Figure 43. Americas IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2021-2026)

Figure 44. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)

Figure 45. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)

Figure 46. United States IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 47. Canada IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 48. Mexico IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 49. Brazil IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 50. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Region in 2026

Figure 51. APAC IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2021-2026)

Figure 52. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)

Figure 53. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)

Figure 54. China IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 55. Japan IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 56. South Korea IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$

millions)

Figure 57. Southeast Asia IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 58. India IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 59. Australia IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 60. China Taiwan IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 61. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Country in 2026

Figure 62. Europe IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2021-2026)

Figure 63. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)

Figure 64. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)

Figure 65. Germany IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 66. France IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 67. UK IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 68. Italy IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 69. Russia IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 70. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026)

Figure 71. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)

Figure 72. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)

Figure 73. Egypt IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 74. South Africa IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 75. Israel IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 76. Turkey IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 77. GCC Countries IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 (\$ millions)

Figure 78. Manufacturing Cost Structure Analysis of IL-17 Inhibitors for Psoriasis in 2026

Figure 79. Manufacturing Process Analysis of IL-17 Inhibitors for Psoriasis

Figure 80. Industry Chain Structure of IL-17 Inhibitors for Psoriasis

Figure 81. Channels of Distribution

Figure 82. Global IL-17 Inhibitors for Psoriasis Sales Market Forecast by Region (2027-2032)

Figure 83. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Forecast by Region (2027-2032)

Figure 84. Global IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Type (2027-2032)

Figure 85. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Forecast by Type (2027-2032)

Figure 86. Global IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Application (2027-2032)

Figure 87. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global IL-17 Inhibitors for Psoriasis Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G39B79B76209EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G39B79B76209EN.html>